Status:

COMPLETED

Statin Discontinuation in Advanced Illness

Lead Sponsor:

University of Colorado, Denver

Collaborating Sponsors:

National Institute of Nursing Research (NINR)

Conditions:

Palliative Medicine

Cardiovascular Disease

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to determine if there is a difference in survival rate at 60 days after enrollment between patients with advanced life-limiting illness for whom statins are discontinued v...

Detailed Description

Currently, over 80% of the population is expected to die of chronic life-limiting illnesses, predominant among which are the various manifestations of cardiovascular disease, cancer, dementia, and chr...

Eligibility Criteria

Inclusion

  • age \>18 years old;
  • have an advanced life-limiting illness;
  • have a life expectancy of \>1 month, AND patient exhibits declining functional status, defined as a reduction in Australia-modified Karnofsky Performance Status (AKPS)22 score to \<80% in the previous 3 months;
  • be on a statin medication for primary or secondary prevention of cardiovascular disease for ≥3 months;
  • have adequately intact cognitive status to provide informed consent and complete the baseline assessment, as evidenced by a Short Portable Mental Status Questionnaire (SPMSQ)23 score of ≥6;
  • provide informed consent; and,
  • speak and read English at or above a grade 5 level (per patient or caregiver report).

Exclusion

  • primary treating physician/care provider estimates their life expectancy as \< 1 month;
  • under the care of a primary treating physician/primary care provider who is unwilling to have the patient enrolled;
  • not consenting;
  • having known active cardiovascular disease or sufficient risk of active cardiovascular disease to require ongoing therapy with statin drugs, in the opinion of the treating physician; OR,
  • exhibiting obvious symptoms of myositis, known liver function test (LFT) abnormalities of \>2.5x the upper limit of normal (ULN), known creatine kinase (CK) abnormalities of \>2.5x ULN, or other contraindications to continuing statins, in the opinion of the treating physician.

Key Trial Info

Start Date :

June 3 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 15 2013

Estimated Enrollment :

381 Patients enrolled

Trial Details

Trial ID

NCT01415934

Start Date

June 3 2011

End Date

July 15 2013

Last Update

September 21 2018

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

University of Alabama, Birmingham

Birmingham, Alabama, United States, 35294

2

San Diego Hospice and the Institute for Palliative Medicine

San Diego, California, United States, 92103

3

University of Colorado, Denver

Denver, Colorado, United States, 80217

4

Kaiser Permanente

Denver, Colorado, United States, 80231